These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results